On July 30, the US Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.
For more information read the FDA announcement and the Johnson & Johnson announcement.
Posted 7/31/2024
An at-home option for cervical cancer screening breaks down barriers to care and offers the same level of precision as screening in the clinic.
